Results 91 to 100 of about 11,456 (188)

Forced degradation study of canagliflozin with the use of HPLC [PDF]

, 2020
In this work a method for determination of canagliflozin and its degradation products by HPLC with UV and MS detector was developed. The developed method was used to study the forced degradation of canagliflozin and to investigate the major degradation ...
Máchalová, Jitka
core  

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton, Louise Thisted, Maria Ougaard, Max Hahn, Kasper Andersen, Johanna Perens, Robert Augustin, Besnik Bajrami, Wolfgang Rist, Michael Christensen, Henrik H. Hansen, Thomas Klein   +11 more
wiley   +1 more source

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S. Bajaj, G. B. John Mancini, Norman C. Wong, April Slee, Fernando G. Ang, Wally Rapattoni, Brendon L. Neuen, Clare Arnott, Vlado Perkovic, Kenneth W. Mahaffey   +13 more
doaj   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Characterization of metabolic parameters in responders and nonresponders treated with canagliflozin monotherapy in drug-naive subjects with Type 2 diabetes

Indian Journal of Endocrinology and Metabolism, 2018
Objectives: The aim of this project is to compare the effect of canagliflozin monotherapy on metabolic parameters between responders and nonresponders with this drug. This study is a prospective, unblinded, observational study.
Eiji Kutoh, Asuka Wada, Teruma Murayama, Jyunka Hayashi   +3 more
doaj   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Canagliflozin (Invokana®): a First-in-Class Anti-diabetic Drug

, 2013
The US Food and Drug Administration have approved (on March 29, 2013) a novel glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the treatment of adults with type 2 diabetes.
Sen, Sukanta
core   +1 more source

The Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy [PDF]

, 2020
Canagliflozin (CANA) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of type II diabetes. There is recent evidence suggesting that Canagliflozin has antiproliferative effects against malignant tumours.
Mekhaeil, Bassem
core   +1 more source

Frailty and low body mass index as key determinants of sodium‐glucose cotransporter 2 inhibitor‐specific adverse event‐related discontinuation in adults aged ≥75 years: A multicenter real‐world retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Hiroki Nabekura, Yuki Kikuchi, Takumi Beppu, Akari Sekishima, Hirotaka Sekishima, Takayuki Nakamura, Fumiko Kogo, Yudai Uehira, Yuri Tanaka, Hideki Yamaguchi, Kazuya Shimoda   +13 more
wiley   +1 more source

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use.
Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang, Cheng‐Jung Ho, Chung‐Hwan Chen, Li‐Nien Chien   +5 more
wiley   +1 more source